gMendel

AI cloud-based end-to-end solution for the detection & medical interpretation of genetic disorders & beyond. Based on any third-party sequencing technology, the gMendel®Test enables real-time analysis of hundreds of molecular barcodes simultaneously in less than 24 hrs. Our technology is simple, practical & cost effective, and has greater detection capabilities than the available technologies, with an ability to be extended, scaled & applied for the detection of multiple genetic disorders & beyond.

The novel combination of genomics & AI is Better: sensitivity 99% vs. 63%; unclassified reads 6% vs. 24%; security, trust & transparency; Faster: 1520 vs. 138 reads/sec; dual approach to achieving scalability & precision; Cheaper: 10x more samples in one flow cell.

Product Roadmap: In 2022, gMendel®Test-SCAN obtained CE mark under EU IVDD, becoming the world’s first IVD certified test for human genetic disorders utilizing Oxford Nanopore. gMendel® has 7 products in the pipeline. Our second product, gMendel®Test- BCT is expected to be certified in early 2024, followed by NBS, NIPT and Cardio (prediction of myocardial infarction). Our ultimate goal is to leverage multi-omics, clinical data, and AI for diagnosis and prediction of any disease.